Business Context and Reporting Period
Company: Phathom Pharmaceuticals, Inc. (PHAT)
Filing Type: Form 8-K (Current Report)
Date of Report: October 25, 2025
Event: Publication of additional analyses from the pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA (vonoprazan) for Non-Erosive Reflux Disease (NERD) in the American Journal of Gastroenterology.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
The report details significant clinical outcomes from the pHalcon-NERD-301 trial involving 772 patients randomized to VOQUEZNA 10 mg, 20 mg, or placebo:
- Heartburn-Free Nights (Week 4): Mean percentages were 59.9% (10 mg) and 56.4% (20 mg) for VOQUEZNA versus 43.3% for placebo (p<0.0001). Median percentages were 70.4% (10 mg), 71.0% (20 mg), and 45.5% (placebo).
- Onset of Effect: Separation from placebo occurred after the first dose. 45.3% (10 mg) and 52.4% (20 mg) of patients experienced a heartburn-free night after the first dose compared to 32.1% on placebo.
- Patient-Reported Outcomes: VOQUEZNA improved total N-GSSIQ scores and subscales for nocturnal symptom severity and concern, though not morning impact. Improvements were sustained through the 20-week extension.
- Durability: Median heartburn-free nights remained above 70% across all treatment groups during the 20-week active extension.
- Safety Profile: VOQUEZNA was generally well tolerated. Common adverse events (≤3% in 4-week phase; ≤5% in extension) included nausea, abdominal pain, constipation, diarrhea, urinary tract infection, upper respiratory tract infection, sinusitis, influenza, nasopharyngitis, and gastroenteritis.
Guidance, Outlook, and Risks
Management Commentary: The publication underscores the burden of nighttime GERD symptoms, affecting up to 80% of GERD patients, and highlights VOQUEZNA's potential role in addressing this unmet need where PPIs and H2RAs often provide inadequate relief.
Risks and Contingencies: The filing includes forward-looking statements subject to risks including:
- Unmet need for new GERD treatments may be lower than anticipated.
- Patient population estimates may be inaccurate.
- Clinical efficacy in practice may differ from trial results.
- Potential for unexpected adverse side effects in commercial use.
- Setbacks in market acceptance or commercialization efforts.
Investor Verification Checklist
- Verify the full text of the article in the American Journal of Gastroenterology to confirm statistical adjustments and study limitations.
- Review the company's most recent Form 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.
- Assess the regulatory pathway and timeline for potential label expansion based on these nocturnal symptom data.
- Monitor upcoming FDA communications regarding the commercialization status of VOQUEZNA for NERD.